Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease

IRCCS Ospedale San Raffaele800 enrolled

Overview

This study aim to investigate the association between plasma NT-proBNP levels and the presence, extent and severity of stenosis in patients with suspected coronary artery disease.

The investigators prospectively measured plasma NT-proBNP levels in consecutive patients referred to the center for elective diagnostic coronary angiography due to symptoms or signs of coronary artery disease over a two- year period. Patients with conditions known to elevate NT-proBNP levels, including heart failure, severe valvular disease, atrial fibrillation, severe chronic kidney disease (eGFR \< 30 mL/min), prior coronary artery bypass grafting, or age over 80 years, were excluded.

Study Type

OBSERVATIONAL

Enrollment

800

Conditions

Chronic Coronary Syndrome Chronic Coronary Total Occlusion Coronary Arterial Disease (CAD)Stable Chronic Angina NT-pro-BNP

Interventions

BNPDIAGNOSTIC_TEST

Measurement of plasma NT-proBNP level.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patient referred for elective coronary angiography due to suspected CAD. * NT-proBNP measurement during hospitalization Exclusion Criteria: * heart failure * severe valvular disease * atrial fibrillation * severe chronic kidney disease (eGFR \< 30 mL/min) * prior coronary artery bypass grafting * age over 80 years

Locations (2)

IRCCS San Raffaele Hospital

Milan, Italy, Italy

COMPLETED

IRCCS San Raffaele Hospital

Milan, Italy, Italy

RECRUITING

Outcomes

Primary Outcomes

Association between plasma NT-proBNP levels and the presence, extension and severity of angiographic lesions in patients with suspected CAD.

Plasma NT-proBNP levels are quantified on the morning before coronary angiography using a highly sensitive electrochemiluminescence immunoassay (ECLIA) method (NT-proBNP, Roche Diagnostics, Germany), employing the Roche Modular Analytics E170 immunoassay analyzer AL. The aim of this study is to explore the association between these levels and the presence (critical vs non-critical), location (prognostic vs non-prognostic), severity (\>70%, 70-99%, 100%) and extent of obstructive lesions detected in a contemporary cohort of patients undergoing coronary angiography for suspected CAD. Coronary angiograms are independently evaluated by two experienced interventional cardiologists (C.G. and C.G.) who are blinded to the NT-proBNP levels.

Time frame: Plasma NT-proBNP levels are quantified on the morning before coronary angiography. The CAD burden is independently evaluated by two experienced interventional cardiologists periprocedurally and immediately after the coronary angiography.

Central Contacts

Carlo Gaspardone

CONTACT

+393389920314 gaspardone.carlo@hsr.it

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.